Investor Centre

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) seeking approval for Bronchitol® for the treatment of patients with cystic fibrosis in the United States.  The FDA has previously granted Bronchitol Orphan Drug designation for the treatment of patients with cystic fibrosis.